Lipid systems have been widely used in drug delivery applications, however issues arise due to instability, insufficient drug loading and burst release of encapsulated drug molecules. Alternatively, established polymeric nanoparticles can control drug release and sustain circulation whilst providing higher stability in biological fluids, however, the biocompatibility is not as high as lipid systems.
We have developed novel PLGAlipid hybrid (PLH) microparticles that combine the stabilising and controlled delivery characteristics of PLGA nanoparticles with the solubilizing effect of lipid droplets. This novel drug delivery formulation can be used in a wide range of therapeutic applications, including combination therapy with tuneable dispersion and controlled drug release.
The PLH microparticles increase the solubility of poorly water soluble drugs by dissolving the drug in the hydrophobic PLGA nanoparticles and lipid droplets. This drug delivery technology has the potential to:
The PLH microparticles have the potential to be used by the pharmaceutical industry as a drug carrier for the delivery of a wide range of hydrophobic drugs. Routes for administration include, oral, implantable and inhalation.
This technology is relevent for:
The team is seeking commercial partners for drug delivery and formulation co-development and licensing opportunities.
A novel hybrid drug delivery formulation that can be used in a wide range of therapeutic applications.